Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144547	GLAXOSMITHKLINE LLC	Oral dosage form for controlled drug release	Sep, 2023 (8 days ago)
US8637512	GLAXOSMITHKLINE LLC	Formulations and method of treatment	Jun, 2028 (4 years from now)

Lamictal Xr is owned by Glaxosmithkline Llc.

Lamictal Xr contains Lamotrigine.

Lamictal Xr has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Lamictal Xr are:

Lamictal Xr was authorised for market use on 29 May, 2009.

Lamictal Xr is available in tablet, extended release;oral dosage forms.

The generics of Lamictal Xr are possible to be released after 14 June, 2028.

Market Authorisation Date: 29 May, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg	12 Feb, 2014	1		14 Jun, 2028	Extinguished

Strength	Dosage	Availability
25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
100MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
200MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
250MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
300MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

LAMICTAL XR family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic